Danaher Corporation (DHR) vs Viridian Therapeutics, Inc. (VRDN)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| DHR | VRDN | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Biotechnology |
| Size band | LARGE | MID |
| Listing | NYSE | Nasdaq CM |
| Country | United States | United States |
| Theme | life-science-tools | rare-disease |
| Price and returns | ||
| Last close | $232.97 | $23.34 |
| Return · 1 week | +3.81% | +12.21% |
| Return · 1 month | +2.66% | +13.47% |
| Return · 3 months | +17.04% | +19.63% |
| Return · year to date | +1.33% | −23.92% |
| Return · 1 year | +5.78% | +3.55% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −4.05% | −31.93% |
| 52-week high | $242.80 | $34.29 |
| 52-week low | $160.93 | $13.18 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $163.77B | $2.64B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $834.36M | $36.84M |
| Employees | 58,000 | 252 |
| Valuation | ||
| Price to earnings · trailing | 39.18× | n/a (negative earnings) |
| Price to earnings · forward | 23.64× | n/a (negative forward earnings) |
| Price to sales | 6.15× | 30.31× |
| Price to book | 2.94× | 3.82× |
| Enterprise value to EBITDA | 22.06× | n/a (negative EBITDA) |
| Enterprise value to revenue | 7.05× | 21.33× |
| PEG ratio | 1.29 | — |
| Earnings per share · trailing | 5.61 | -3.39 |
| Profitability | ||
| Gross margin | 58.51% | — |
| Operating margin | 19.78% | −44460.56% |
| Profit margin | 15.89% | −469.63% |
| Return on equity | 7.61% | −65.74% |
| Return on assets | 3.95% | −30.16% |
| Growth | ||
| Revenue growth | +5.50% | +278.70% |
| Earnings growth | +59.70% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 52.97 | 36.96 |
| Current ratio | 1.65 | 16.95 |
| Dividend yield | 0.74% | 0.00% |
| Payout ratio | 25.67% | — |
| Trend and volatility | ||
| RSI · 14 | 62.01 | 35.98 |
| ADX · 14 | 31.94 | 24.69 |
| 50-day average | $216.74 | $21.96 |
| 200-day average | $201.19 | $22.83 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.78% | 3.86% |
The full DHR analysis
Everything this table leaves out for Danaher Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the DHR argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full DHR analysisThe full VRDN analysis
Everything this table leaves out for Viridian Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the VRDN argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full VRDN analysis